DQHK(SZ:000985) Zheng Quan Shi Bao Wang·2025-09-16 09:44Core Viewpoint - Daqing Huake's performance in the first half of 2025 shows a slight decline in revenue but an increase in net profit, indicating resilience in a challenging market environment [1][2]. Group 1: Financial Performance - In the first half of 2025, Daqing Huake achieved operating revenue of 959 million yuan, a year-on-year decrease of 0.85% [1]. - The company reported a net profit of 9.064 million yuan, reflecting a year-on-year increase of 12.99% [1]. - The non-recurring net profit was 7.9774 million yuan, which represents a year-on-year decrease of 8.5% [1]. Group 2: Business Operations and Strategy - Daqing Huake primarily engages in the production and sales of petrochemical products, including C5 and C9 series resins and polypropylene powder, with applications in various industrial sectors [1][2]. - The company has invested in expanding its production capabilities, including a 10,800-ton/year butadiene extraction facility and a capacity expansion project for isoprene hydrogenation, now at 35,000 tons/year [2]. - Daqing Huake aims to enhance its C5/C9/propylene industrial chains, focusing on functional, specialized, and high-end applications, while fostering collaborations with research institutions and industry leaders [2]. Group 3: Asset Management - Daqing Huake attempted to sell machinery assets from its pharmaceutical division, initially listed at an assessed value of 11.8351 million yuan, but failed to attract buyers [3]. - The company reduced the asking price to 10.6516 million yuan in a second attempt, which also did not yield any interested parties, leading to the termination of the sale process [3].